Foresite Capital Fund IV, L.P. - Dec 31, 2024 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James Tananbaum
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
291M shares
Disclosed Ownership
19.5M shares
Ownership
6.7%
Form type
SCHEDULE 13G/A
Date filed
2/14/2025, 02:20 PM
Date of event
Dec 31, 2024
Next filing
May 15, 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 2.9% 8.33M 8.33M 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 2.9% 8.33M 8.33M 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.8% 8.13M 8.13M 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.8% 8.13M 8.13M 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 1% 3.02M 3.02M 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 1% 3.02M 3.02M 0 /s/ James Tananbaum James Tananbaum, Managing Member
James Tananbaum 6.7% 19.5M 19.5M 0 /s/ James Tananbaum James Tananbaum